
Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.
Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.
This study explored the statistical association of key social determinants of health with specific health outcomes to validate impact and then created weighted categorical matrices.
Published: August 15th 2025 | Updated:
Published: March 9th 2021 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.